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ABSTRACT: The first kinase inhibitor drug approval in 2001
initiated a remarkable decade of tyrosine kinase inhibitor drugs for
oncology indications, but a void exists for serine/threonine protein
kinase inhibitor drugs and central nervous system indications.
Stress kinases are of special interest in neurological and
neuropsychiatric disorders due to their involvement in synaptic
dysfunction and complex disease susceptibility. Clinical and
preclinical evidence implicates the stress related kinase
p38αMAPK as a potential neurotherapeutic target, but isoform
selective p38αMAPK inhibitor candidates are lacking and the
mixed kinase inhibitor drugs that are promising in peripheral
tissue disease indications have limitations for neurologic
indications. Therefore, pursuit of the neurotherapeutic hypothesis
requires kinase isoform selective inhibitors with appropriate neuropharmacology features. Synaptic dysfunction disorders offer a
potential for enhanced pharmacological efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the
interacting cellular components of the synaptic pathophysiological axis, to be modulated. We report a novel isoform selective
p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative
and spatial memory deficits in two distinct synaptic dysfunction mouse models. A synthetic scheme for biocompatible product
and positive outcomes from pharmacological screens are presented. The high-resolution crystallographic structure of the
p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor,
and suggests a structural explanation for MW150’s exquisite target selectivity. As far as we are aware, MW150 is without
precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related
behavior.
KEYWORDS: Signal transduction, cognitive dysfunction, protein kinase, crystallography, chemical synthesis, pharmacology
The approval of Gleevac in 2001 provided the first kinaseinhibitor drug.1 Gleevec is a multikinase inhibitor that
binds at the active site of tyrosine kinases.2,3 Subsequent
approved kinase inhibitor drugs shared the features of active
site binding and multikinase targeting.2−4 These early historical
development trends contributed to prevailing bias and
perspectives.2−4 For example, one concern was that in vivo
function might require drug candidates to have multikinase
activity.2 Another concern was that development of kinase
inhibitor drugs would be limited if one targeted the active site,
due to the level of sequence similarity of catalytic domains
across the kinome family and the high levels of ATP in the
eukaryotic cell.2,4,5 However, the kinase active site continues to
be highly druggable as documented by the approved kinase
inhibitor drugs that target the active site.3 In addition, progress
in recent years indicates the feasibility of generating new kinase
inhibitor drug candidates with even greater selectivity through
medicinal chemistry optimization driven by structural biology
approaches.2,6 Regardless, the above concerns and the estimate
that only about 2% of small molecule drugs have adequate
blood brain barrier distribution7 have led to the perspective that
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kinases are not a promising class of central nervous system
(CNS) drug development targets.
Clearly, major gaps remain in the protein kinase inhibitor
drug pipeline,3−6 including: (1) the limited number of validated
protein kinase targets outside oncology indications; (2) the
paucity of serine/threonine (S/T) protein kinase inhibitor
drugs; and (3) the absence of approved CNS kinase inhibitor
drugs. Successful targeting of CNS S/T kinases represents an
intertwined triple challenge. First, there is the inherent tissue
barrier challenge of CNS drug development.7 Second, there is
an insufficient number of single kinase-specific in vivo small
molecule tools for target validation studies.3,5,6 Initial target
validation requires evidence for modulation by selective probes.
While genetic knock down and chemical proteomics studies are
key for discovery, inherent limitations of the latter approaches,
including the potential of an observed phenotype being indirect
due to an effect on the kinase interactome, do not allow them
to stand alone for initial target validation.5,10,11 The ideal is to
complement the broader discovery approaches with direct in
vivo molecular probe approach, but this can be technically
challenging. Third, intracellular S/T kinases are nodes in an
integrated system11 in which the in vivo function of a widely
distributed enzyme is dependent on the context of tissue
physiological state as well as molecular partners and cellular
localization. Because alteration of phenotype does not require
full activation of all kinase nodes in the network, it is not
currently possible to forecast what percentage inhibition of the
fractionally activated network will result in restoration of
homeostasis. It is critical, therefore, that individual CNS S/T
protein kinases be examined for their potential pharmacological
modulation with selective in vivo probes and that CNS drug
candidates with these attributes be developed.3,6,8,10
A potential neurotherapeutic kinase target identified across
diverse disease areas is p38αMAPK, a S/T protein kinase
implicated in various stress-induced activations within neurons
and glia, the cellular components of the synaptic physiologic
axis that manifests dysfunction across multiple dementia and
neurodegenerative disorders.6,8,10,12−23 However, deconvolu-
tion of p38αMAPK’s exact signaling function for a given in vivo
physiological or pathophysiological role is complicated by a
number of factors,6−10 including: (1) wide tissue distribution;
(2) presence as a mixture of phosphorylated and non-
phosphorylated states that differ in activity; (3) protein−
protein interactions that control subcellular localizations; and
(4) the presence of parallel interactive signaling pathways
responding to the same cellular stressors as part of an
integrated system-wide network. Regardless of the mechanistic
knowledge gaps, recent evidence from in vivo studies with
selective p38αMAPK inhibitor molecular probes6 demonstrated
attenuation of neuroinflammation, synaptic dysfunction, and
cognitive deficits, thereby providing a more direct pharmaco-
logical link among mechanism of action, pharmacodynamics,
and efficacy. However, issues of metabolic stability, CYP
substrate status, and oral bioavailability limit the potential use
of these in vivo probes for drug development in complex
diseases that require extended exposure, repeat administration,
and low potential for drug−drug interactions via CYP substrate
or inhibitor status.
The accumulating body of evidence for CNS p38αMAPK as
a target offers the potential of an unusual pharmacological
strategy where the same inhibitor might be used to attenuate
stressor induced pathophysiological responses in two interact-
ing cells, glia and neurons, within the synaptic structure.
Targeting such a localized neuropathophysiology axis could
Figure 1. Repurposing of a nonkinase CNS experimental therapeutic to CNS kinase inhibitor.
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offer an enhanced potential for efficacy.3,6 For example, an
enhanced potential for efficacy could arise if both the
endogenous glia and neuron pathways are key to pathophysi-
ology progression during a common intervention time window.
In addition, a potential for an extended efficacy time window
might occur if the importance of activated glia is key early in
progression and neuronal stress is more critical at later time
windows of progression, allowing for the same drug to have
extended pharmacodynamics via action in overlapping but
distinct pathology progression time windows. Dosing, the
pharmacological basis of therapeutics, would allow the probing
of such possibilities once a candidate therapeutic is obtained.
However, the future testing of various neurotherapeutic
hypotheses involving p38αMAPK requires a priori the
availability of a highly selective p38αMAPK inhibitor candidate
with appropriate pharmacological properties.
As a further step toward addressing the hypothesis of
p38αMAPK as a potential neurotherapeutic target, we report
here the synthesis and functional characterization of MW01-18-
150SRM (referred to as MW150), a novel selective inhibitor of
the p38αMAPK isoform with promising pharmacological
features and in vivo CNS efficacy. Memory loss is the clinical
hallmark of Alzheimer’s disease (AD), and drugs approved for
AD employ the attenuation of memory loss as a qualifying end
point. Therefore, we used a detailed behavioral assessment of
memory as the initial relevant pharmacodynamic readout for
MW150 efficacy. Two independent mouse models of AD
relevant pathophysiology progression were employed. One is a
transgenic model with rapid pathophysiology progression. The
other is a humanized knock-in model that employs endogenous
promoters and exhibits age-related pathophysiology progres-
sion over an extended time frame. The in vivo efficacy of
MW150 is consistent with a true hippocampus-dependent
mechanism of action in attenuation of memory deficits. Key
pharmacological screens of MW150 indicate the potential for
compatible use with approved AD drugs. In aggregate, the
results are consistent with future pursuit of MW150 as a logical
drug candidate. Molecular level characterization of MW150 by
high resolution crystallography of the human p38αMAPK/
MW150 complex documents MW150’s active site occupancy
with key intermolecular interactions, indicates that the active
site bound inhibitor is in a relative low energy conformation,
and provides a rational explanation for the molecular basis of
MW150 exquisite selectivity. Overall, the results are consistent
with MW150 being a unique candidate for the in vivo study of
CNS function and dysfunction, provide a precedent for kinase
active site targeting to attain highly selective kinase inhibitors
with in vivo CNS function, and support the concept of
attenuating behavioral deficits through the use of protein kinase
inhibitors.
■ RESULTS AND DISCUSSION
Rationale and Overview. The scaffold repurposing
approach6,12 that delivered MW150 employed high-resolution
crystallography of complexes containing human p38αMAPK
combined with small molecule design using pharmacoinfor-
matics considerations. Synthesized inhibitors were curated by
activity and pharmacological screening.6,12 The initial hit,
MW069a,12 was obtained by alternative placement of the
pyridine substituent on the pyridazine core of a safe, brain
penetrant experimental therapeutic, MW18924 (Figure 1).
MW189 attenuates neurotoxic overproduction of cytokines by
activated glia back toward normal, has no reported direct
therapeutic effects on neurons, and is negative in kinome-wide
screens. The alternative placement of the pyridine ring to
produce MW069a generated a key H-bonding interaction with
the p38αMAPK hinge region backbone and allowed occupancy
by the phenyl substituent of the nearby hydrophobic pocket
(see PDB entry 4EWQ). MW069a lacks inhibitor activity with
p38αMAPK(T106M), the enzymatically active point mutant in
which the introduction of a bulky amino acid at the entrance to
the hydrophobic pocket prohibits access by ligand aromatic
substituents, provided a link between crystal structure of the
complex and in vitro inhibition activity.12 Although MW069a
has in vivo function in an Alzheimer’s disease relevant screening
assay,12 it is a mixed kinase inhibitor like extant p38αMAPK
inhibitor drugs and has a limited safety with dose escalation.
Therefore, pharmacological safety was improved next6 by
reduction in the size of the exocyclic amine substituent. The
p38αMAPK specificity and affinity was also improved6 through
the introduction of a 2-naphthyl substituent at the R6 position
(Figure 1). The simplest of the resultant naphthylpyridazi-
nylpyridines (MW181, PDB 4F9Y; MW108, PDB 4F9W)
retain the key target interactions, engage in a dose dependent
manner the endogenous p38αMAPK in activated glia, and are
selective as demonstrated by kinome-wide activity screens and
inactivity with the p38αMAPK(T106M) drug resistant knock-
in mouse glia.6 However, further exploration of in vivo function
and the potential for preclinical drug development was limited
by their potential for metabolism and distribution as evidenced
by human liver microsome (HLM) screening assay outcomes of
T1/2 = 18 min (MW181) and T1/2 = 33 min (MW108).
As summarized herein, a final optimization by synthesis and
screening yielded MW150 that has improved HLM stability
(T1/2 > 60 min) and oral bioavailability (>50%) as well as an
incrementally improved p38αMAPK inhibition activity with
retention of target selectivity, safety, and brain penetrance. A
summary of key MW150 features described in the following
sections is provided in Table 1. Attempts at further improve-
ment in metabolic stability potential were addressed through
synthesis and testing of R3 amine analogues and R6
fluoronaphthyl analogues of MW150 (Supporting Information
Table S1) that did not yield significant improvement in
multiproperty features. For example, fluoronaphthyl analogues
did not improve HLM stability and, in some cases, resulted in
loss of activity. MW150, containing a R3 piperazine substituent
and R6 2-naphthyl substituent, represents the best in class for
metabolic and bioavailability potential with retention of isoform
selective p38αMAPK IC50 activity. Overall, the results
demonstrate that the active site of this protein kinase can be
targeted to generate an isoform selective inhibitor with in vivo
CNS efficacy. The molecular and pharmacological profile
describes a unique deliverable appropriate for future investiga-
tional new drug (IND) enabling preclinical development.
Chemistry. MW150, 6-(4-methylpiperazin-1-yl)-3-(naph-
thalen-2-yl)-4-(pyridin-4-yl) pyridazine (8 = MW150), and its
hydrochloride salt (9) were made via an eight step, multigram
scale, synthetic scheme (Scheme 1) with a final product (purity,
96%) appropriate for biological investigations. The details and
the characterization of intermediate and final products in
Scheme 1 are provided in Methods. Briefly, 2-naphthoyl
chloride was reacted with N,O-dimethylhydroxyl amine to
provide the Weinreb amide 2 in quantitative yield. Treatment
of 2 with the lithio salt of 4-picoline gave the expected ketone
3, which was further reacted with sodium hydride and ethyl
bromoacetate to form the ketoester intermediate 4. Reaction of
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4 with hydrazine gave the expected dihydropyridazinone 5,
which was oxidized to 6 with aqueous NBS in DMSO.
Conversion to the bromide 7 occurred following treatment
with phosphorus oxybromide in acetonitrile. The free base of
the final product 8 was obtained when bromide 7 was treated
with 1-methylpiperazine. The crystalline substance was treated
with HCl to give the final salt form 9. The final hydrochloride
salt form (9) was confirmed by elemental analysis and has
acceptable water solubility (>1 mg/mL) for use in the
biological studies reported here. The attractiveness of the
synthetic scheme for future development purposes is its flexible
nature and the potential for use of various GMP compatible
reagents, solvents, and conditions.28 The flexible nature of the
scheme combined with the atomic resolution crystal structure
of the human protein target and the small molecule candidate
(Figure 2; PDB 4R3C) also provides a platform for facile
incorporation of any future optimizations that might be desired.
Structure. The crystal structure of the complex containing
human p38αMAPK and MW150 (PDB 4R3C) is of high
quality (Table 2 and Figure 2). As discussed recently,29 the
issue of ligand geometry accuracy and the evaluation of
parameters involved in protein ligand contacts are critical to
interpretation of crystallography results in terms of target
recognition and the implications for mechanism. Further,
widely used virtual screening approaches in drug discovery are
critically dependent on the robustness of experimental database
entries based on crystallography. The paucity of isoform
selective kinase inhibitors or CNS penetrant kinase inhibitors
with in vivo function make the robustness of data evaluation
even more critical. Table 2 statistics demonstrate a good fit of
the diffraction data and the structural model for p38αMAPK.
Further, there is a good fit of the inhibitor MW150 diffraction
data (Figure 2). The results are consistent with an energetically
favorable conformation of the piperazine ring in the target
bound form of the inhibitor. Overall, the quality of the
Table 1. Summary Data Sheet for MW150
MW (base) 381.47
MW (hydrochloride hydrate) 490.43
cLogP 2.18
PSA 45.15
chemical stability stable at pH (1−13), 24 h, 37 °C
solubility (hydrochloride hydrate) >l mg/mL
pKa (potentiometrie;
spectrophotometric)
3.83, 7.27; 3.62, 7.27
apparent target affinity Ki = 101 nM (p38αMAPK)
target cocrystal structure PDB 4R3C; 2 Å
kinome target class selectivity negative except p38αMAPK
functional GPCR off-target activity negative
Caco-2 permeability/P-gp substrate highly permeable; not P-gp substrate
MDCK permeability/BCRP
substrate
highly permeable; not BCRP substrate
human liver microsome stability T1/2 > 60 min
human CYP substrate negative: 1A2, 2B6, 2D6, 2C8, 2C9,
2C19, 3A4
human CYP inhibition negative: 1A2, 2B6, 2D6, 2C8, 2C9,
2C19, 3A4
MAO-A/MAO-B inhibition negative
AMES test negative
oral Bioavailability >50%
Brain/plasma ratio >0.9
Scheme 1a
aReagents and conditions: (i) DIPEA, DCM: 100%; (ii) LDA, THF, −78 °C, 83%; (iii) 60% NaH, 1,4-dioxane, 20 °C, ethyl 2- bromoacetate, 1 h;
(iv) N2H4 AcOH, ethanol, reflux, 20 h; (v) NBS, DMSO/H2O, 72 h = 97%; (vi) POBr3, ACN, reflux, 10 h, 60%; (vii) 1-methylpiperazine, EtOH,
reflux = 18 h, 94%; (viii) 2.5 equiv conc HCl, anhydrous isopropanol, 80 °C, 96%.
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diffraction data and its fitting to the structural model provides
increased confidence in evaluations of key interactions between
human p38αMAPK and MW150.
Inspection of the crystallographic structure reveals that
MW150 and human p38αMAPK retain the key complementary
interactions that drove the discovery approach. Key conserved
interactions within the active site (Figure 3A) include the
hydrogen bond interaction between the pyridine ring nitrogen
of MW150 and the amide backbone at Leu108-Met109 (Figure
3B) and occupancy of the proximal hydrophobic pocket by the
naphthyl substituent of MW150 (Figure 3C). MW150 appears
to use a single hydrogen bond interaction with the hinge region
and does not induce significant localized conformational
changes in the human p38αMAPK active site. Notably, prior
work showed that the crystallographic experimental approach is
validated for the detection of such localized conformational
changes in the hinge region should they be present.6 The
significant space filling of the hydrophobic pocket by the
naphthyl substituent is illustrated in the surface representation
generated by residues within a 5 Å distance (Figure 3C). The
greater space filling function of the naphthyl group, in the
context of the other interactions such as the canonical hydrogen
bonding with the hinge region, contributes to target affinity and
selectivity. The structural results, combined with the large scale
target screening data presented in the following section, suggest
that the intimate pocket occupancy is a key contributor to
specificity via the exclusion of MW150 binding to other targets
in the proteome that either lack, or have less accommodating,
proximal pockets. Overall, the most parsimonious model for
this precedent of kinase isoform selectivity via targeting of the
active site is one that maximizes of key chemical complemen-
tarities between MW150 and p38αMAPK.
Kinome Target Selectivity. A large-scale hierarchical
kinase screen approach6 was used to demonstrate (Table 3)
the selectivity of MW150 for p38αMAPK within the protein
and lipid kinome. Briefly, 301 protein and lipid kinases
representative of all major human kinome branches as well as
isoforms of individual families were screened using substrates
optimized for each kinase. The database accession numbers of
the protein and lipid kinases shown in Table 3 are provided in
Supporting Information Table S2. The only validated positive
hit from the large scale kinome screen with an IC50 < 1000 nM
was p38αMAPK (Table 3). The estimated Ki from kinetic
analyses (Supporting Information Figure S1) is 101 nM.
Especially noteworthy (Table 3) is the failure of MW150 to
inhibit significantly the other p38MAPK isoforms. The IC50 for
p38αMAPK inhibition is approximately 10-fold better than that
for p38βMAPK, 14-fold better than that for p38δMAPK, and 6-
fold better than that for the atypical NLK. Further, MW150
does not inhibit the enzymatically normal p38αMAPK-
(T106M) point mutant in which the gatekeeper amino acid
threonine is mutated to a bulkier methionine residue, thereby
blocking access by the naphthyl substituent to the hydrophobic
pocket. The kinome screening results are, therefore, consistent
with the high resolution crystal structure of the complex.
The secondary assays for quantitative cellular activity of
MW150 were done using a relevant CNS cell population,
activated glia. As shown in Figure 4A, treatment of activated
glia with MW150 inhibits in a concentration-dependent
manner the ability of the endogenous p38αMAPK to
phosphorylate an endogenous substrate, MK2. These results
Figure 2. Stereo view of omit map for MW150 bound in the active site
of human p38αMAPK. The map represents the difference electron
density (mesh) contoured at 2.5σ. The analysis indicates the goodness
of fit between the model and experimental data and is consistent with
an energetically favorable conformation for MW150 (purple). Key
amino acids in p38α MAPK (green) indicated: Met 109, involved in
H-bonding with MW150, and Thr 106, gate-keeper for access to the
hydrophobic pocket.
Table 2. Crystallographic Data and Refinement Statistics for
the Human p38αMAPK-MW150 Complex (PDB accession
code 4R3C)
data collection
space group P212121
wavelength (Å) 0.97872
cell dimensions 65.85, 74.51, 77.80, 90, 90, 90
resolution (Å) 30.00−2.05
outer resolution 2.09−2.05
completeness (%) 99.8 (100.0)
Rmerge 0.062 (0.599)
mean (I/σ) 23.17 (2.37)
redundancy 4.8 (4.9)
no. of unique reflections 24 314
refinement
resolution (Å) 29.93−2.06
Rwork 17.5
Rfree 21.6
RMSD bond lengths (Å) 0.009
RMSD bond angles (deg) 1.39
Figure 3. Human p38αMAPK active site occupancy by MW150 (PDB
4R3C). (A) Connolly surface representation of the active site of
p38αMAPK containing MW150. (B) Close-up view of the
p38αMAPK hinge region near Met109 (left) and the pyridine
substituent of MW150 (right) that are involved in hydrogen bond
interaction. The gray mesh represents the experimental 2Fo-Fc
electron density contoured at 1.2σ. (C) Surface created by amino
acids within 5 Å of the naphthyl group of MW150. This perspective
highlights the volume that the naphthyl substituent of MW150
occupies within the p38αMAPK hydrophobic pocket that is proximal
in space to the hydrogen-bonding region shown in panel (B). The blue
mesh surrounding MW150 was built from the experimental 2Fo-Fc
electron density contoured at 1.5σ.
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demonstrate that MW150 is able to engage its endogenous
kinase target in a relevant physiological state. MK2 is the
proximal next step in the intracellular p38αMAPK signal
transduction cascade shown to mediate lipopolysaccharide
(LPS)-induced increases in production of proinflammatory
cytokines such as interleukin-1β (IL-1β). In this context, IL-1β
represents a surrogate pharmacodynamic end point for the
p38αMAPK signal transduction cascade. As shown in Figure
4B, MW150 treatment blocked in a concentration-dependent
manner the increased IL-1β production by activated glia. The
IC50 values for these MW150 cellular activities are 332 nM
(MK2) and 936 nM (IL-1β), values which are consistent with
the in vitro Ki of 101 nM for p38αMAPK.
As a further derisking of potential off target activities,
MW150 was also subjected to a large-scale screen for GPCRs,
the largest single target class for approved CNS drugs, in order
to address the potential of unanticipated out-of-target-class
activity. MW150 showed no agonist or antagonist activity
against any of the 166 GPCRs tested in the functional cellular
assay (Supporting Information Table S3). The results indicate
the extremely low potential for off-target crossover to this
major CNS drug target class.
Pharmacological Screens. The United States Food and
Drug Administration (FDA) recommends30 testing new
molecular entities as potential substrates or inhibitors for a
critical set of CYP isoforms that are involved in drug and food
metabolism, thereby anticipating dosing, drug−drug interac-
tions, and potential adverse events in future drug development.
This is especially true for certain CYP isoforms such as
CYP2D6 that are known to encode functional polymorphisms
and contribute to pharmacogenetic variance in drug efficacy or
toxicology. Paradoxically, when small molecule lead compounds
are optimized during multiproperty medicinal chemistry
refinement to improve CNS penetrance, an unintended
outcome can be increased potential for CYP substrate
status.25,26 CYP2D6 also can be disproportionately involved
in the metabolism of CNS drugs.26 Therefore, CYP2D6
substrate status is a No Go decision point in CNS drug
development and is one of the FDA recommended CYPs for
screening. While the substrate or inhibitor status for the other
recommended CYPs may not be as critical, the outcomes can
inform the design of future dosing and adverse pharmacology
experiments.
As anticipated based on pharmacoinformatics,25,26 MW150
was not found to be a substrate of CYP2D6. Remarkably,
MW150 is also not a substrate for any of the other key CYPs
recommended for testing in FDA guidance. When screened
using the standard assays described in Methods, MW150
exhibited a T1/2 > 60 min for all of the recommended CYPs.
Positive controls for each of the CYPs and their respective T1/2
values were as follows: CYP1A2, ethoxyresorufin (T1/2 = 2);
CYP2B6, benzphetamine (T1/2 = 17); CYP2D6, dextro-
methorphan (T1/2 = 4); CYP3A4, midazolam (T1/2 = 4);
CYP2C8, paclitaxel, (T1/2 = 39); CYP2C9, diclofenac (T1/2 =
16); and CYP2C19, omeprazole (T1/2 = 21). MW150 was also
found not to be a CYP inhibitor when the recommended set of
CYP isoforms were examined (Figure 5). The CYP isoform
positive control inhibitors were as follows: CYP1A2, α-
naphthoflavone; CYP2B6, thio-TEPA; CYP2D6, quinidine;
CYP2C8, montelukast; CYP2C9, sulfaphenazole; CYPC19,
(+)-N-3-benzylnivanol; CYP3A4, ketoconazole. These remark-
able results from both CYP substrate and CYP inhibitor
analyses are positive indicators of lowered risk for use of
MW150 in future in vivo drug combination studies which are
expected for complex disease investigations.
The aggregate effect of CYP-based status was next evaluated
in standardized liver microsome assays. Testosterone was used
as a validation control for both rat and human microsomal
preparations, and percent remaining of test compounds was
determined by LC-MS based on the peak area ratio to the
internal standard propranolol. MW150 has a human liver
microsome stability T1/2 > 60 min and a rodent liver
microsomal T1/2 = 43 ± 4 min. The intrinsic clearance
(CLint) was estimated as 0.02 ± 0.00 mL/min/mg protein. We
concluded that the liver microsome stability was acceptable for
additional pharmacological studies.
A quantitative cellular pharmacology parameter that is critical
for CNS targeting is the standard assay used to filter drug
candidates for acceptable cell permeability and efflux pump
substrate status. Most small molecule drugs predominately
move via passive diffusion through cellular membranes that
comprise tissue barriers. However, if the drug is an efflux pump
substrate, it is removed and eventually excreted from the body.
Figure 4. Concentration-dependent cellular activity of MW150. (A)
MW150 treatment suppresses the phosphorylation of MK2, a
p38αMAPK substrate whose phosphorylation (activation) is increased
in response to LPS activation of glia. Serial dilutions were added to
BV2 microglial cells stimulated with 100 ng/mL LPS, and the levels of
pMK2 at 1 h determined by ELISA analysis. (B) MW150 treatment
attenuates the downstream increase in proinflammatory cytokine
production, a mechanism of action pharmacodynamic end point.
Levels of IL-1β at 16 h were determined by ELISA. Data are expressed
as percent of maximal activity (=activity after LPS stimulation +
control vehicle treatment) and are representative of at least two
independent experiments. Open circle = no LPS + veh; black circle =
LPS + veh; gray circle = LPS + MW150.
Figure 5. CYP inhibition summary.
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Poor permeability due to molecular properties and efflux pump
substrate status can individually or in combination with other
factors contribute to a drug’s inadequate CNS penetrance.
Therefore, MW150 was subjected to both the classical Caco-2/
P-gp screening system and the more recently developed
MDCK/BCRP screening assay.
The data summarized in Table 4 demonstrate that MW150
has high cell permeability and is not a substrate for P-gp efflux
pump. For apical to basolateral (A → B) permeability, the test
agent is added to apical side and permeation determined by
LC/MS/MS measured on basolateral side; the opposite is done
for (B → A). P-gp substrate status is then determined by
measuring the effect of the standard inhibitor 1 μM valspodar
on bidirectional flux. The percent recovery of MW150 is 71%
and 61%, respectively.
As shown in Table 5, MW150 also has high cell permeability
for MDCK cells and is not a substrate for the BCRP efflux
transporter. The standard inhibitor Ko143 (10 μM) was used
to probe bidirectional flux in this assay. Percent recovery of
MW150 was 66% and 67%, respectively.
The results from molecular and cellular property screening
assays for MW150 warranted progression to in vivo
pharmacological screens. First, a preliminary screen for oral
bioavailability potential was done in rat. Pharmacokinetic
parameters were determined after intravenous (iv) and oral
(po) administration at 5 mg/kg. Animals were fasted prior to
MW150 administration and up to 4 h post administration. All
animals showed normal activity during the study. The
concentration of MW150 in plasma samples was determined
by LC-MS/MS, and the parameters estimated by a non-
compartmental analysis. The screening data show that MW150
has a half-life in excess of 3 h and an oral bioavailability of
>50%. Second, the pharmacokinetic screening results were used
in the design of a brain-to plasma ratio screen for tissue
penetrance potential. MW150 was administered at the same 5
mg/kg dose and levels measured in plasma and brain samples 3
h post administration. The estimated brain/plasma ratio of >0.9
indicates that MW150 is able to distribute across the blood-
brain barrier. Clearly, MW150 has attractive oral bioavailability
potential, warranting a full dose dependent kinetic analysis in
future investigational new drug development investigations.
Prior to analysis for efficacy, MW150 was also screened in a
modified SHIRPA test paradigm6 to minimize the impact of
unanticipated adverse pharmacology and unintended influences
on the interpretation of behavioral studies. This consensus
approach to filtering for frank adverse pharmacology prior to
candidate selection provides a degree of derisking for future
investigational new drug enabling studies and allows fuller
Table 4. Caco-2 Permeability/P-gp Substrate Summary for MW150
sample concn (μM) time (h) mean A → B Papp (10
−6 cm s−1)a mean B → A Papp (10
−6 cm s−1)a efflux ratiob notes
MW150 5 2 33.5 31.2 0.9 high permeability
MW150 + valspodar 5 2 27.6 23.0 0.8 not a P-gp substrate
aApparent permeability. bPapp(B → A)/Papp(A → B).
Table 5. MDCK Permeability/BCRP Substrate Summary for MW150
sample concn (μM) time (h) mean A → B Papp (10
−6 cm s−1)a mean B → A Papp (10
−6 cm s−1)a effiux ratiob notes
MW150 5 2 20.7 25.1 1.2 high permeability
MW150 + Ko143 5 2 26.1 24.3 0.9 not a BCRP substrate
aApparent permeability. bPapp(B → A)/Papp (A → B).
Figure 6. MW150 treatment suppresses associative and spatial memory deficit in APP/PS1 Tg mice. Daily oral administration of either saline or
MW150 (2.5 mg/kg) was done from age 8 weeks to 3−4 months. Associative and spatial memories were then assessed, respectively, through (A)
contextual fear memory and (B) RAWM. Saline treated APP/PS1 mice exhibited cognitive deficits for both types of memory compared to saline
treated-type (WT) mice, as evidenced by a significantly lower percent of freezing during assessment of fear memory, and by higher number of errors
in the RAWM task. However, treatment of APP/PS1 mice with MW150 resulted in suppression of the deficits, as seen by the percent of freezing and
RAWM performance indistinguishable from that of WT mice.
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interpretation of animal behavior studies used as an efficacy end
point. Briefly, C57BL/6 mice were administered saline
(control) or MW150 (50 and 150 mg/kg, 20- and 60-fold
above the efficacy dose) and clinical observation documented.
Normal individual variances among mice in all groups were
observed in total distance traveled or center versus edge
occupancy, but no differences or adverse events were detected
among saline or MW150 treated mice over a 24 h period of
observation.
We conclude that MW150 is a chemically stable and orally
bioavailable p38αMAPK inhibitor that exhibits excellent cell
permeability, absence of efflux pump and CYP liabilities,
adequate metabolic stability and possessing minimal risk for
adverse pharmacology liabilities. The aggregate outcomes,
therefore, justified in vivo evaluation of efficacy.
Behavior as Pharmacodynamic Test of in Vivo
Efficacy. Memory loss is the clinical hallmark of AD. Most
importantly for drug discovery, the current FDA approved AD
drugs used the attenuation of memory loss as a qualifying end
point. We therefore decided to use a behavioral assessment of
memory as the initial pharmacodynamic readout for MW150
efficacy. Two distinct AD-relevant mouse models were tested:
the APP/PS1 transgenic (Tg) mouse and the APPNLh/NLh ×
PSP264L/P264L knock-in (KI) mouse. Both models show synaptic
dysfunction and cognitive deficits.6,27 The APP/PS1 Tg model
overexpresses amyloid-beta (Aβ). It is an amyloid deposition
model in which selective p38αMAPK inhibition has been linked
to attenuation of long-term potentiation (LTP) and cognitive
dysfunction brought about by amyloid-beta (Aβ) stress.6 In
contrast, the genetic APP/PS KI model uses endogenous
promoters with no overexpression of the amyloid precursor
protein (APP). It reflects physiological levels of APP and is an
aging model that allows testing at either early or late stage
pathology progression.27
The Tg mouse model was tested in a preventative paradigm,
as previously described.6 Because both associative and spatial
memory are known to be affected in AD patients, we tested the
effects of MW150 on contextual fear learning, a hippocampus-
dependent task assessing associative memory, and in the two-
day RAWM task that assesses spatial memory. Briefly, wild type
(WT) and APP/PS1 littermate mice were treated with MW150
(2.5 mg/kg, oral, daily) or vehicle starting at 8 weeks of age and
continuing until 3−4 months when cognitive impairment is
present. Behavioral assessments were done with the radial arm
water maze (RAWM) and contextual fear conditioning tests as
described.6 MW150 treatment improved the Tg mice perform-
ance in both cognitive tests (Figure 6).
The specificity of a physiological axis response to therapeutic
intervention is key to relevance of an animal model
pharmacodynamic end point to future clinical studies. There-
fore, it is worth noting additional pharmacodynamic effects of
MW150 that provide a firmer foundation and translational
value. Specifically, MW150’s behavioral effects are selective and
consistent with hippocampal mediated mechanisms. For
example, treatment with MW150 did not affect the perform-
ance of WT mice (Figure 6), consistent with MW150 treatment
altering disease-relevant mechanisms instead of a more general
effect on memory. Further, there was no effect on cued fear
memory, a hippocampus-independent type of memory. Other
analyses reinforce the disease relevant physiological axis (Figure
7). For example, the sensory threshold was similar among
different groups of mice, indicating there was no modification
of the ability to perceive the shock (Figure 7). Additionally,
MW150 treatment did not influence the visible platform task,
which assesses sensory, motor, and motivational mechanisms,
and did not influence open field tests, which assess locomotor
activity and anxiety (Figure 7C−F). Finally, the effect of
MW150 treatment is dose dependent for behavior end points
(Supporting Information Figure S2).
The second AD-relevant mouse model used to test MW150
intervention was in older mice where cognitive deficits are
already present. The humanized APP/PS1 KI mouse model is
Figure 7. Control behavioral analyses for MW150 suppression of associative and spatial memory deficits in APP/PS1 transgenic mice. No difference
was detected between groups when tested for cued fear memory (A), sensory threshold (B), visual-motor-motivational deficits with the visible
platform test (speed and time to the platform are shown in (C) and (D), respectively), and exploratory behavior, as shown by a similar percentage of
time spent in the center compartment (E) and the number of entries into the center compartment (F).
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driven by endogenous promoters of the APP and PS1 genes,
generating progressive pathology without overproduction. The
KI mice exhibit a spatial memory deficit in the RAWM by the
age of 11 months. The deficits can be attenuated by
pharmacological interventions that target cognitive dysfunction
brought about by excessive proinflammatory cytokine produc-
tion.28 Treatment of 11−12 month old mice with MW150 (2.5
mg/kg, ip, daily for 14 days) suppressed the cognitive
impairment, assessed by RAWM 3 days after the last
administration. The MW150-treated mice exhibit RAWM
behavior indistinguishable from WT mice (Figure 8).
From the perspective of end points that reflect the scientific
foundation of currently approved AD therapeutics, the
independently obtained results in two distinct pathology
progression models demonstrate the ability bring about
pharmacological efficacy with MW150 repeat dosing. Further,
the results in a battery of behavioral tests are consistent with a
true hippocampus-dependent mechanism of action in attenu-
ation of memory deficits. Repeat dosing with MW150 did not
bring about any observed adverse events within the targeted
physiological axis or control behaviors in aged or diseased
animals. The selective improvement in cognitive behavior was
also brought about with no effect on amyloid plaque load
(Supporting Information Figure S3).31
■ SUMMARY AND CONCLUSIONS
MW150 is a unique protein kinase inhibitor with in vivo
efficacy in two distinct AD relevant models at a low dose with
repeat administration and no observed adverse events in aged
mice. Behavior is a complex and technically challenging end
point. This is one motivation for our performing efficacy testing
in independent animal models of AD related pathophysiology
and for examination of diverse behavioral controls in the
experimental design. Overall, the results summarized here
indicate a selective effect of MW150 intervention on cognitive
performance via a hippocampus-dependent mechanism of
action, consistent with prevailing perspectives on human
dementia progression and drug regulatory approval paradigms.
We have described a pharmacological intervention relation-
ship for a comparatively simple single stressor−single kinase−
neuropathophysiology paradigm, but the availability of MW150
provides an embarkation point for placing into context the
various other roles hypothesized for activated p38αMAPK in
complex CNS disease phenotypes. For example, MW150 is
currently being used to address the potential of attenuating
neuropsychiatric disorder phenotypes involving neuronal
p38αMAPK activation. In the long term, extended application
of this unique protein kinase inhibitor to diverse CNS
pathophysiology progression mechanisms might better inform
us about which p38αMAPK mediated dysfunctions are more
tractable for intervention and are more clinically relevant.
MW150 is efficacious when administered either before full-
fledged pathology is evident or after pathology is already
present, reflecting potential for use in either a prevention mode
or disease treatment mode. The promising outcomes with
repeat dosing administration might be a reflection of MW150’s
pharmacological profile and protein kinase isoform selectivity,
or it might reflect parallel pharmacological action on stress
activated glia and neurons in close proximity within the
synaptic pathophysiology unit. While both possibilities are
intriguing and desired, their relative contributions cannot be
fully interpreted based on the results reported here. Regardless,
a degree of derisking for future IND enabling analyses and a
potential for use in a polypharmacy environment, which
characterizes complex CNS disease interventions, are evident in
the battery of pharmacological screen outcomes such as lack of
substrate status for key CYPs defined by regulatory guidelines,
good bioavailability potential, promising CNS exposure, and no
observed frank adverse events.
Target selectivity is demonstrated by a variety of approaches,
including large-scale kinome and GPCR screens in conjunction
with cellular target engagement and surrogate pharmacody-
namic end points. The structural basis of MW150 kinome and
isoform selectivity appears to reside in a combination of two
key interactions that engage the p38αMAPK hinge region and a
proximal hydrophobic pocket. Hinge region H-bond engage-
ment is a common theme among the diverse chemical classes of
p38αMAPK inhibitors that exhibit in vivo function.3,5,6,9
MW150 fulfills this role through use of the pyridine substituent
nitrogen atom. No localized conformational changes are
observed with MW150 binding to the hinge region, such as
the glycine flip observed with other promising p38αMAPK
inhibitors. The finding is consistent with previous work6 that
showed this localized conformational change in the kinase is
not required for selective p38αMAPK inhibition. A second
interaction of MW150 with p38αMAPK is occupancy of a
proximal hydrophobic pocket by a vicinal 2-naphthyl
substituent. This pocket is not exploited by ATP, in contrast
to the hinge region engagement which is used by ATP. The
shape and space filling features of the 2-naphthyl group allow
extensive filling of the hydrophobic pocket. A similar pocket is
found in other p38MAPK isoforms and a limited set of other
kinases, but the shape and properties of the hydrophobic
pockets in other kinases do not appear as accommodating of
the 2-naphthyl substituent. The pocket accessibility and space
Figure 8. MW150 treatment suppresses spatial memory deficit in
APP/PS1 knock-in (KI) mice. MW150 administration (A) to APP/
PS1 KI mice (2.5 mg/kg; ip, daily for 14 days; n = 11, gray squares)
suppressed cognitive deficits (B) seen in APP/PS1 KI mice treated
with vehicle (gray circles, n = 12) and was indistinguishable from WT
mice treated with vehicle (black triangles, n = 14). Mice were tested in
a 2-day RAWM assay of spatial reference memory starting 3 days after
the last treatment. Cognitive deficits in the KI mice treated with
vehicle were evidenced by a significantly higher number of errors in
RAWM performance compared to KI mice treated with MW150 (#p <
0.05, ##p < 0.005, ###p < 0.001) or WT mice treated with vehicle (*p <
0.05, **p < 0.005, ***p < 0.001).
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filling features of the 2-naphthyl substituent of MW150,
therefore, appear to add a structure based selectivity filter.
Additional interactions observed among other p38αMAPK
inhibitors, such as those resulting in DFG-out conformations,
are not observed in the high-resolution structure presented
here. This finding is consistent with previous work2,3,6 that
showed the DFG-out conformation does not always correlate
with kinase inhibition and is not required for isoform selectivity.
Overall, the presence of the vicinal pyridinyl and 2-naphthyl
substituents in the context of the pyridazine scaffold is the most
parsimonious explanation of what MW150 features provide
selective target engagement, while MW150 molecular proper-
ties25 and specific aspects of its first pass metabolism26 appear
to drive bioavailability and pharmacological exposure in order
to deliver the highly selective in vivo efficacy.
In conclusion, the results presented here add to a body of
knowledge that raises the rational possibility of p38αMAPK
inhibitor drugs for CNS indications might be one in which
efficacy, either in a palliative or disease modifying mode, is a
reasonable anticipation. Current perspectives on p38αMAPK
inhibitor drugs are influenced by perceived failures in some
disease indication areas even while others continue to show
promising outcomes.32,33 In this regard, it should be noted that
drug development termination at the clinical trials stage is not
equivalent to efficacy failure. For example, termination in
clinical development can be due to business decisions on the
part of pharmaceutical companies or to regulatory issues such
as a trial achieving efficacy but not surpassing current standards
of care. Such terminations are distinct from failure to reach the
trial efficacy goals. In this context, the approved AD drugs are
acetylcholinesterase inhibitors and most recent and ongoing
clinical trials target the amyloid pathway and generally fail to
reach efficacy. Therefore, an established standard for
attenuation of pathophysiology progression remains a future
goal for the AD field. Additionally, the gap in CNS kinase
inhibitor drug developmnent25 remains. In this context, it is
clearly worth pursuit of p38αMAPK inhibitors similar to
MW150 as CNS therapeutic candidates. Further, the promising
pharmacological profile of MW150 also makes it a potential
complementary intervention that might enhance outcomes
from prevailing AD therapeutic development approaches or be
used in combination therapies for this complex disease.
■ METHODS
Synthesis and Characterization of MW150 for Biological
Studies (Scheme 1). The experimental detail for the title compound
MW150 is presented here. The synthesis of additional compounds
used in the investigation are presented in the Supporting Information.
N-Methoxy-N-methyl-2-naphthamide (2). A mixture of 2-
naphthoyl chloride (1, 35 g, 0.18 mol) and N,O-dimethylhydroxyl-
amine hydrochloride (21.5 g, 0.22 mol) in dichloromethane (1L) was
stirred, cooled in an ice bath, and treated with diisopropylethylamine
(58 g, 0.45 mol, 81 mL) dropwise over 30 min. The mixture was
warmed to 20 °C over 2 h then stirred an additional 1 h. The solvents
were evaporated, and the residual solid was dissolved in ethyl acetate
(500 mL) and water (500 mL). The organic layer was separated and
washed with 1 N HCl (300 mL), water (300 mL), and brine (200
mL). The organic phase was dried (Na2SO4) and evaporated to leave
the product as a light tan oil (2, 39.5 g, 100%). Mass (ESI) m/z 216
(M + H)+.
1-(Naphthalen-2-yl)-2-(pyridin-4-yl)ethan-1-one (3). A solution of
4-picoline (15.6 g, 168 mmol, 16.2 mL) in anhydrous THF (1 L)
under nitrogen atmosphere at −78 °C was treated with a solution of
freshly prepared LDA [from a solution of diisopropyl amine (25.4 g,
252 mmol, 35.4 mL)] in THF (140 mL) under nitrogen atmosphere
in an ice bath treated with n-butyllithium solution (2.5 M in hexanes,
100 mL, 252 mmol and stirred for 30 min) over 30 min via cannula.
The mixture was stirred at −78 °C for 1 h and was treated with N-
methoxy-N-methyl-2-naphthamide (2, 40 g, 186 mmol) in THF (160
mL) dropwise over 1.5 h while ensuring the temperature was
maintained at or below −75 °C. The mixture was then allowed to
warm to 20 °C over 4 h and stirred an additional 16 h at this
temperature. Saturated ammonium chloride solution (100 mL) was
added to the mixture and allowed to stir 30 min. The solvents were
evaporated in vacuo to approximately 20% of the original reaction
mixture volume and the residue was dissolved in ethyl acetate (1 L)
and water (600 mL). The organic layer was separated and washed with
water (600 mL). The product was extracted from the organic layer
with 1 N HCl (2 × 300 mL). The combined acid extracts were
neutralized with solid sodium bicarbonate to pH = 8. The precipitated
product was filtered, washed with water (2 × 50 mL), and dried under
vacuum for 16 h to leave a light yellow solid (3, 34.5 g, 83%). 1H
NMR (300 MHz, CDCl3) δ 8.58 (dd, J = 4.4, 1.8 Hz, 2H), 8.53 (s,
1H), 8.05 (dd, J = 8.5, 1.8 Hz, 1H), 8.00−7.84 (m, 3H), 7.66−7.55
(m, 2H), 7.25 (m, 2H), 4.43 (s, 2H). Mass (ESI) m/z 248 (M + H)+.
LC/MS Rt = 3.37 min.
Ethyl 4-(Naphthalen-2-yl)-4-oxo-3-(pyridin-4-yl)butanoate (4). A
solution of 1-(naphthalen-2-yl)-2-(pyridin-4-yl)ethan-1-one (3, 34 g,
138 mmol) in anhydrous 1,4-dioxane (750 mL) under nitrogen
atmosphere was treated with sodium hydride (60% in mineral oil, 6.8
g, 170 mmol) and stirred for 1 h with occasional venting to prevent
hydrogen accumulation. The mixture, which had a yellow precipitate,
was treated with ethyl 2-bromoacetate (28 g, 170 mmol, 18 mL) and
stirred for 18 h. A solution of saturated ammonium chloride (100 mL)
was added and the mixture stirred for 30 min. The solvents were
evaporated to approximately 80% of the original volume and the
residue was diluted with ethyl acetate (600 mL) and water (400 mL).
The mixture was filtered through Celite (ethyl acetate wash) to
remove a small amount of yellow precipitate. The organic layer was
separated and the product was extracted with 1 N HCl (4 × 100 mL).
The combined acid extracts were neutralized with solid sodium
carbonate (pH = 9) and the product was extracted with ethyl acetate
(2 × 300 mL). The combined organic extracts were washed with brine,
dried over Na2SO4 and evaporated. The crude residue (26 g) was used
in the next step without purification or characterization.
6-(Naphthalen-2-yl)-5-(pyridin-4-yl)-4,5-dihydropyridazin-3(2H)-
one (5). A solution of ethyl 4-(naphthalen-2-yl)-4-oxo-3-(pyridin-4-
yl)butanoate (4, 26 g, 51 mmol) in ethanol (175 mL) and acetic acid
(8 mL) was treated with hydrazine hydrate (110 g, 1.2 mol, 110 mL)
and refluxed for 20 h. A beige precipitate formed. The mixture was
cooled to 20 °C and filtered to collect the product which was washed
with ice cold methanol (40 mL) and acetonitrile (40 mL) and air-dried
to leave a cream colored powder (5, 15.0 g, 36% for two steps). 1H
NMR (300 MHz, CDCl3) δ 8.76 (bs, 1H), 8.57 (d, J = 5.3 Hz, 2H),
7.98 (dd, J = 8.5, 1.8 Hz, 1H), 7.95 (s, 1H), 7.85 (d, J = 8.5 Hz, 1H),
7.86−7.76 (m, 2H), 7.55−7.46 (m, 2H), 7.21 (dd, J = 4.4, 1.2 Hz,
2H), 4.68 (d, J = 6.5 Hz, 1H), 3.10 (dd, J = 17.0, 7.7 Hz, 1H), 2.90
(dd, J = 17.0, 1.8 Hz, 1H). Mass (ESI) m/z 302 (M + H)+. LC/MS Rt
= 3.11 min.
6-(Naphthalen-2-yl)-5-(pyridin-4-yl)pyridazin-3(2H)-one (6). A
round-bottom flask equipped with a stir bar was charged with 6-
(naphthalen-2-yl)-5-(pyridin-4-yl)-4,5-dihydropyridazin-3(2H)-one
(5, 14.5 g, 48 mmol), water (7 mL), and DMSO (250 mL). The
mixture was stirred and treated with N-bromosuccinimide (42 g, 233
mmol). The reaction mixture turned yellow and a slight exotherm was
noted while all solid contents went into solution. After stirring for 20
h, the mixture was poured into a stirring solution of water (1 L) and
saturated sodium bicarbonate solution (500 mL) at such a rate that
effervescence remained under control. The white precipitate that
formed was collected on a glass frit, washed with water (2 × 50 mL),
and air-dried to leave product (6, 13.9 g, 97%). 1H NMR (300 MHz,
CDCl3) δ 11.13 (bs, 1H), 8.55 (bs, 2H), 7.80 (dd, J = 9.1, 2.1 Hz,
1H), 7.76−7.68 (m, 3H), 7.55−7.45 (m, 2H), 7.16 (dd, J = 8.8, 2.0
Hz, 1H), 7.09 (d, J = 5.9 Hz, 2H), 7.05 (s, 1H). Mass (ESI) m/z 300
(M + H)+. LC/MS Rt = 2.88 min.
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6-Bromo-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine (7). A
round-bottom flask equipped with a stir bar was charged with
phosphorousoxybromide (29 g, 102 mmol) and anhydrous acetonitrile
(310 mL). The mixture was stirred until all solids were dissolved. To
this solution was added 6-(naphthalen-2-yl)-5-(pyridin-4-yl)pyridazin-
3(2H)-one (6, 13.3 g, 44.5 mmol), and the mixture was heated to
reflux for 18 h. The reaction mixture was cooled in an ice bath, treated
with ice (150 g), and stirred for 1 h. The reaction mixture volume was
reduced to 50% of the original volume by evaporation under vacuum.
The residual mixture was neutralized with solid sodium carbonate (pH
= 9), and the product was extracted with ethyl acetate (2 × 100 mL).
The combined organic layers were washed with brine (100 mL), dried
(Na2SO4), and evaporated. The crude product was purified by silica
gel (EM Baker, 230−400 mesh) chromatography eluted with a
gradient of ethyl acetate in hexanes (1:1 to 9:1) to leave the product as
a light beige solid (7, 9.6 g, 60%). 1H NMR (300 MHz, CDCl3) δ 8.59
(dd, 2H, J = 4.3, 1.8 Hz), 8.03 (d, J = 1.4 Hz, 1H), 7.85−7.65 (m, 3H),
7.72 (s, 1H), 7.58−7.47 (m, 2H), 7.33 (dd, 1H, J = 8.5, 1.8 Hz), 7.15
(dd, 2H, J = 4.7, 1.8). Mass (ESI) m/z 364 (M + H)+. LC/MS Rt =
3.71 min.
6-(4-Methylpiperazin-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)-
pyridazine (8 = MW150). A solution of 6-bromo-3-(naphthalen-2-yl)-
4-(pyridin-4-yl)pyridazine (7, 11.5 g, 32 mmol) in 95% ethanol (170
mL) was treated with 1-methylpiperazine (15.9 g, 158 mmol, 18 mL)
and heated to reflux for 18 h. Upon cooling to 20 °C, approximately
90% of the ethanol was evaporated under reduced pressure. The
residue was dissolved in ethyl acetate (200 mL) and aqueous saturated
sodium bicarbonate solution (150 mL). The organic layer was
separated and washed with water (2 × 200 mL). Minutes after the
second water wash, the product precipitated from the organic layer
while still in the separatory funnel. The solid was collected on a
medium glass frit via suction filtration, washed with ethyl acetate (2 ×
20 mL), and dried under vacuum (1 mm Hg) at 50 °C for 12 h. The
desired material 8 (MW150) was obtained as a pale yellow solid (11.5
g, 94%). 1H NMR (CDCl3, 500 MHz) δ 8.53 (dd, J = 1.7, 4.4 Hz, 2H),
7.92 (s, 1H), 7.78 (dd, J = 1.8, 7.7 Hz, 1H), 7.71−7.67 (m, 2H), 7.47−
7.41 (m, 2H), 7.34 (dd, J = 1.7, 8.5 Hz, 1H), 7.13 (dd, J = 1.7, 4.4 Hz,
2H), 6.86 (s, 1H), 3.83 (t, J = 4.7, 4.7 Hz, 4H), 2.62 (t, J = 5.0, 5.1 Hz,
4H), 2.39 (s, 3H). Mass (ESI) m/z 382.20 (M + H)+. HRMS (mass)
calculated for C24 H23 N5: 381.1953. Found: 381.19603. Elemental
analysis calculated (%) for C24H23N5: C, 75.56; H, 6.08; N, 18.36.
Found C, 73.70 H, 6.31; N, 17.93. LC/MS Rt = 2.58 min, mp 188.5−
189 °C.
6-(4-Methylpiperazin-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)-
pyridazine hydro chloride hydrate (9). In a round-bottom flask fitted
with condenser and dry tube, compound 6-(4-methylpiperazin-1-yl)-3-
(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine (8, 9.1 g, 23.8 mmol) was
suspended in 95 mL of anhydrous isopropanol (99.5%, Aldrich) and
heated to 89 °C with stirring until dissolved. To the resulting solution,
ultrapure HCl (12 N, JT Baker Ultrex II, product 6900-05) (2.5 equiv,
5.1 mL, 59.63 mmol) was added in-portion, inducing formation of
solids in suspension. The resulting solution was stirred at 81 °C for 10
min, cooled to ambient temperature, and placed on an ice-bath for 2.5
h. The suspension was then transferred to 4 °C for an additional 10 h.
The resulting yellow precipitate was filtered on a medium frit sintered
glass funnel using a house vacuum, immediately washed three times
with ice-cold anhydrous isopropanol (3 × 35 mL), followed by ice-
cold anhydrous ether (3 × 50 mL), and air-dried using house vacuum
for 7 h. The product was then dried in a glass desiccator containing
silica gel in vacuo until the compound gave a constant weight. Product
9 obtained as a yellow powder (11.12g, 96%), HPLC purity > 98%
(LC/MS). ESI m/z (MeOH) 382.2 (M+H)+. 1H NMR (500 MHz,
MeOD) δ 8.75 (dd, J = 1.5, 5.0 Hz, 2H), 7.96 (s, 1H), 7.91−7.83 (m,
6H), 7.58−7.52 (m, 2H), 7.38 (dd, J = 1.8, 8.4 Hz, 1H), 4.86 (m, 2H),
3.71 (m, 2H), 3.57 (m, 2H), 3.28 (m, 2H), 3.01 (m, 3H). HRMS
(mass) calculated for C24 H23 N5: 381.19535. Found: 381.1955.
Elemental analysis calculated (%) for C24H29Cl2N5O2: C, 58.78; H,
5.96; N, 14.28; Cl, 14.46; O, 6.52. Found: C, 58.89 H, 5.89; N, 14.15;
Cl, 14.27; O, 7.05. mp 240 °C, decomposes.
Aqueous solubility was determined by Absorption Systems as
previously described.6 Briefly, 1 mg of MW150 powder was combined
with 1 mL of buffer to make a 1 mg/mL mixture and shaken on a
Thermomixer overnight at room temperature (22 °C). The pH of the
water was also measured before addition of test compound and after
overnight equilibration. The samples were then passed through a 0.2
μm PTFE syringe filter and diluted in duplicate 10-, 100-, and 10 000-
fold into a mixture of 1:1 buffer: acetonitrile prior to analysis, and
assayed by LC-MS/MS using electrospray ionization against standards
prepared in a mixture of 1:1 assay buffer/acetonitrile. Standard
concentrations ranged from 1.0 μM down to 3.0 nM.
The acid dissociation constant (pKa) of MW150 was determined by
pION Inc. (Billerica, MA) using both potentiometric and UV methods
as previously described.6 The cosolvent was methanol, experimental
pH range was 1.7−12.8, assay vials were thermostated at 25 °C, and
ionic strength was 0.15 M KCl. Eight titrations were used to calculate
the pKa using the Yasuda−Shedlovsky technique.34 Quality control
and calibrants used were phosphate, 0.5 N KOH, 0.5 N HCl, and the
FDA approved drug quinine. The pKa values obtained from
spectrophotometric experiments are in excellent agreement with
those derived from potentiometric titrations.
Chemical stability was determined by Absorption Systems (Exton,
PA) as described previously.6 Briefly, at a final concentration of 0.001
M at neutral (pH 7), 0.1 N NaOH (pH 13.0), or 0.1 N HCl (pH 1.0)
at 37 °C, conditions were tested, with samples taken for analysis at 0,
1, 3, 6, and 24 h. MW150 is chemically stable over a wide range of pH.
Crystallography and Structure Determination. Experiments
involving target−drug complex formation, data collection, and data
processing were done using the standard operating protocol as
validated previously6 for the determination of atomic resolution
ligand−kinase crystal structures. Protein purification6 was done using a
combination of affinity-based adsorption chromatography (HisTrap;
GE Healthcare), gel filtration (HiPrep 26/10 column; GE Healthcare),
and ion exchange chromatography (Q Sepharose; GE Healthcare).
In Vitro Activity. Large-scale screens for off-target activity within
the kinome were done using the hierarchical screening protocol
described previously.6 MW150 was screened in a commercially
performed (Millipore Profiler, now Eurofins) high throughput system
that included 301 protein and lipid kinases representative of all major
kinome branches as well as isoforms of individual families. Substrates
were optimized for each kinase. The final concentration of MW150 in
the profiler screen (20 000 nM) was achieved by serial dilution of a
DMSO stock solution to the final assay concentration in 2.0% DMSO/
Tris buffer. Preliminary hits from the profiler screen (<40% kinase
activity remaining) were validated as true positives or false hits by a
follow-up determination of an IC50 value. An estimated Ki value was
determined on confirmed positives with IC50 < 1000 nM. A similar
hierarchichal approach6 was used for functional GPCR agonist and
antagonist screens. The GPCR Profiler screen uses real-time calcium
flux FLIPR assay. MW150 was tested at 12 500 nM for agonist and
10 000 nM for antagonist activity. Similar to kinase profiler, apparent
hits were determined as true positive or false hits by follow-up IC50
determination compared to a control agonist or antagonist for the
given GPCR. Details are provided in Supporting Information Table
S3.
MW150 was tested for CYP substrate status with the standard FDA
recommended series of CYPs using the commercial service provider
CEREP (Redmond, WA). MW150 (0.1 μM) was tested in duplicate
against CYP1A2, CYP2B6, CYP2D6, CYP2C8, CYP2C9, CYP2C19,
and CYP3A4. For each screen, a reference compound was at a
concentration of 0.1 μM. T1/2 was estimated from the slope of the
linear portion of the curve for compound remaining (%) versus time,
assuming first order kinetics. Inhibitor status of MW150 with the FDA
recommended CYPs (CYP1A2, CYP2B6, CYP2D6, CYP2C8,
CYP2C9, CYP2C19, and CYP3A4) was done by Absorption Systems,
Inc. (Exton, PA) using a standardized human liver microsomal assay.
Briefly, MW150 (10 μM) and a CYP-specific probe substrate (at
concentration approximating its Km value) were incubated at 37 °C for
10−30 min, reactions terminated and metabolites monitored by LC-
MS/MS. Positive controls for each CYP were performed separately
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using a known inhibitor. Monoamine oxidase (MAO) inhibition status
of MW150 was determined by Cyprotex (Watertown, MA) by
assaying the ability of MW150 (0.01−25 μM) to inhibit the conversion
of probe substrate kynuramine, using the nonselective MAO inhibitor,
tranylcypromine, as a positive control.
Human plasma protein binding using rapid equilibrium dialysis was
done by Absorption Systems (Exton, PA) in a 96-well dialysis plate
assay for plasma protein binding. Briefly, plasma (300 μL) containing
the test and control articles was loaded into dialysis plate wells and
PBS (500 μL) added to each corresponding receiver chamber,
incubation done for 4 h at 37 °C, and aliquots of both chambers
processed and analyzed by LC-MS/MS.
Stability analyses in human liver microsome (HLM) and rat liver
microsome (RLM) assays were performed by Absorption Systems
(Exton, PA). Briefly, MW150 (1 μM) in 100 mM potassium
phosphate, pH 7.4, 5 mM magnesium chloride was incubated at 37
°C in a shaking water bath after initiation of reaction by the addition of
1 mM NADPH, and time points taken at 30, 45, and 60 min. Reaction
termination was done by addition of an equal volume of acetonitrile
containing 0.1% formic acid, samples processed and analyses by LC-
HRAMS to monitor loss of parent compound and appearance of
metabolites. Percent of remaining parent compound is calculated
relative to t = 0 min, with assays being done in duplicate. The
validation control (testosterone for human and rat) was assayed by
LC-MS/MS using electrospray ionization. The peak area response
ratio to internal standard propranolol at each time point was compared
to the response ratio at time 0 to determine the percent remaining.
Graph Pad (San Diego, CA) was used to calculate the half-life, and
data were fit to a single-phase exponential decay equation. The
intrinsic clearance (CLint) was calculated based on CLint = k/D, where
k is the elimination rate constant and D is protein concentration.
Cell Based Activity. MW150 inhibition of lipopolysaccharide
(LPS)-induced responses was tested in the murine microglial BV-2 cell
line as previously described.6 Briefly, cells were treated with either
saline vehicle control or 100 ng/mL LPS (Salmonella enterica serotype
typhimurium, Sigma-Aldrich: EU/mg of LPS is 600 000), in the
absence or presence of increasing concentrations of MW150, cells
harvested after 1 h of stimulation for analysis of pMK2 and after 16 h
for measurement of proinflammatory cytokine IL-1β using kits from
Meso Scale Discovery (MSD; Gaithersburg, Maryland).
Cell permeability and efflux pump susceptibility were determined by
the standard Caco-2 two-way permeability analysis in the absence and
presence of a known P-gp inhibitor, valspodar, with monitoring of
parent drug by HPLC/MS/MS. Similarly, the BCRP-MDCK cell
system was used to determine MDCK cell permeability and potential
substrate status for the efflux pump BCRP (breast cancer resistance
protein) using two-way permeability measurement in the absence or
presence of the known BCRP inhibitor, Ko143, with monitoring of
parent drug by HPLC/MS/MS. The data shown are from experiments
performed as a commercial service by Absorption Systems (Exton,
PA).
The Ames test for genetic toxicology potential was done using a
bacterial reverse mutation assay to evaluate the potential of MW150 to
induce or reverse mutations with and without metabolic activation.
Briefly, the ability to induce reverse mutations at loci of two strains of
Salmonella typhimurium TA98 and TA100 was tested. MW150 was
tested ± metabolic activation at concentrations up to 5 μg/plate. The
positive controls, 2-nitroflurene for TA98 and sodium azide for
TA100, and vehicle control were within expected ranges. Data
presented are from commercial service assays performed by
BioReliance, Inc. (Rockville, MD).
In Vivo Studies. The oral bioavailability of MW150 after
intravenous (iv) and oral (po) administration in male Sprague−
Dawley rats was done by Absorption Systems (Exton, PA). Briefly,
MW150 (5 mg/kg) was administered to male rats (3 rats per
treatment group; total N = 6) using MW01-2-151SRM as an internal
standard. Animals were fasted for a minimum of 12 hours prior to
administration until 4 h post dose. All animals showed normal activity
during the study. Blood was collected via jugular vein cannulation at 5
min, 15 min, 30 min, 1 h, 3 h, and 6 h, and plasma generated and
stored at −60 to −80 °C. Samples were analyzed by LS-MS/MS, and
the pharmacokinetic parameters were estimated by a noncompart-
mental analysis. The brain-to-plasma ratio in male Sprague−Dawley
rats was determined following a single oral administration of 5 mg/kg.
Plasma and brain tissue samples were collected at 3 h post
administration. Brain tissue was weighed, methanol/water (20:80)
added to 4 mL/gram, and the sample homogenized (4 °C) using a
Virsonic 100 ultrasonic homogenizer and then frozen at −80 °C.
Homogenates were subjected to acetonitrile precipitation and
supernatants analyzed by LC-MS/MS.
Behavior as pharmacodynamic test of in vivo efficacy was performed
in two mouse models. The APP/PS1 transgenic mouse (Watterson et
al.6) and the humanized knock-in mouse APPNLh/NLh × PS1P264L/P264L
and their WT controls were used as previously described.6,27 Repeat
administration was done via intraperitoneal route. In compliance with
animal use guidelines, the number of mice used was minimized by not
administering MW150 to WT mice based on previous results in similar
studies with the APP/PS1 KI mice. At the start, each experimental
group contained mice of either sex, with the numbers of males and
females in each group matched as closely as possible. Treatments and
assays were done by personnel who were blind to genotype and drug
treatment conditions.
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